In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serono Deals Its Way Into Oncology

Executive Summary

It ought to be hard to convince an oncology-focused biotech to license its crown jewel to a firm without experience developing oncology drugs, but Serono SA was able to do just that-twice in the span of eight days-when it in-licensed Phase II and Phase III oncology programs, respectively, from Micromet AG and CancerVax Corp. in December.
Advertisement

Related Content

European Consolidation: Serious Competition for Big Pharma?
European Consolidation: Serious Competition for Big Pharma?
Will Pharma Split Spur Altana Into Action?
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
Schering: Addressing the Specialist Challenge
Schering: Addressing the Specialist Challenge
Antegren: Shaking Up the MS Market?
Deal Early, Less Often: ZymoGenetics' Broad Deal with Serono
Antegren: Shaking Up the MS Market?
Micromet: Coping with the Fallout When a Partner is Acquired

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel